{"gene":"AFG3L2","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":1999,"finding":"AFG3L2 encodes a 797-amino-acid mitochondrial protein homologous to paraplegin and yeast Afg3p/Rca1p, localizes to the mitochondrial compartment, and maps to chromosome 18p11; immunofluorescence established its mitochondrial subcellular localization.","method":"Immunofluorescence, EST database screening, radiation hybrid mapping","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization experiment; single lab, moderate methods","pmids":["10395799"],"is_preprint":false},{"year":2008,"finding":"AFG3L2 assembles with paraplegin into a hetero-oligomeric m-AAA protease complex in the inner mitochondrial membrane and also forms homo-oligomeric complexes; loss of AFG3L2 in mice causes impaired axonal development with delayed myelination and poor radial axonal growth, whereas paraplegin loss causes only mild late-onset axonal degeneration, explained by AFG3L2's higher neuronal expression and ability to support both homo- and hetero-oligomerization.","method":"Afg3l2 null and missense knock-in mouse models, histology, electron microscopy, functional comparisons with paraplegin-deficient mice","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — two independent murine genetic models with defined cellular phenotypes, replicated mechanistic interpretation","pmids":["18337413"],"is_preprint":false},{"year":2009,"finding":"Haploinsufficiency of Afg3l2 in mice causes respiratory chain dysfunction, increased reactive oxygen species production, and dark degeneration of Purkinje cells, establishing that a 50% reduction in m-AAA protease activity is sufficient to trigger mitochondria-mediated cerebellar neurodegeneration.","method":"Afg3l2 heterozygous mouse model, ROS measurements, electron microscopy, cerebellar functional assays","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 — clean KO/haploinsufficient model with defined cellular phenotype and multiple orthogonal readouts","pmids":["19625515"],"is_preprint":false},{"year":2010,"finding":"Heterozygous missense mutations in AFG3L2 (in its proteolytic/M41 peptidase domain) cause SCA28; m-AAA-deficient yeast expressing mutant human AFG3L2 homocomplex show respiratory deficiency, proteolytic impairment, and respiratory chain complex IV deficiency, confirming the proteolytic domain is critical for substrate handling.","method":"Yeast complementation assay, respiratory growth assays, complex IV activity measurement, homology modeling","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 1–2 — yeast reconstitution with mutagenesis, multiple functional readouts, replicated across five families","pmids":["20208537"],"is_preprint":false},{"year":2011,"finding":"A homozygous AFG3L2 Y616C mutation causes a hypomorphic variant with oligomerization defects: AFG3L2(Y616C) complexes form impaired homo-oligomers and, to a greater extent, impaired hetero-oligomers with paraplegin, as demonstrated in yeast and patient fibroblasts.","method":"Yeast complementation assay, blue native PAGE in patient fibroblasts, oligomerization analysis","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1–2 — yeast functional assay plus patient fibroblast native gel analysis, two orthogonal systems","pmids":["22022284"],"is_preprint":false},{"year":2012,"finding":"AFG3L2 is required for mitochondrial ribosome assembly and mitochondrial protein synthesis in Purkinje cells; conditional Afg3l2 knockout in Purkinje cells causes cell-autonomous neurodegeneration preceded by mitochondrial network fragmentation and defects in mitochondrially encoded respiratory chain subunits.","method":"Conditional Purkinje-cell-specific Afg3l2 knockout mouse, constitutive knockout, mitochondrial translation assay, mitoribosome assembly analysis, live imaging of mitochondrial morphology","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1–2 — conditional KO with defined cellular phenotype, multiple orthogonal methods including ribosome assembly and translation assays","pmids":["23041622"],"is_preprint":false},{"year":2012,"finding":"Loss of AFG3L2 in mouse embryonic fibroblasts causes mitochondrial network fragmentation secondary to respiratory dysfunction and consequent OPA1 processing, which reduces mitochondrial Ca2+ uptake capacity by leaving a subset of mitochondria disconnected from the ER; OPA1 overexpression rescues Ca2+ buffering but not respiration.","method":"Afg3l2−/− MEFs, Ca2+ imaging, permeabilized-cell Ca2+ uptake assay, OPA1 overexpression rescue, mitochondrial morphology analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — KO MEFs with multiple orthogonal methods, rescue experiment with OPA1","pmids":["22678058"],"is_preprint":false},{"year":2014,"finding":"AFG3L2-deficient Purkinje cells have impaired mitochondrial Ca2+ buffering due to mitochondrial depolarization and altered organelle trafficking to dendrites; partial genetic silencing of mGluR1 or ceftriaxone-mediated reduction of glutamate stimulation reduces Ca2+ influx and rescues ataxia in SCA28 mice, placing AFG3L2 upstream of the Ca2+ excitotoxicity pathway.","method":"Afg3l2 haploinsufficient mouse, Ca2+ imaging in cultured Purkinje cells, mGluR1 genetic silencing, ceftriaxone pharmacological treatment, behavioral assays","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 — epistasis via genetic and pharmacological rescue in vivo and in vitro, multiple orthogonal approaches","pmids":["25485680"],"is_preprint":false},{"year":2014,"finding":"SPG7 processing (cleavage and activation) upon assembly into the m-AAA complex requires AFG3L2 and is regulated by tyrosine phosphorylation of AFG3L2; a SPG7 Q688 variant bypasses this phosphorylation-dependent regulation, constitutively activating the complex and elevating ROS and ATP production.","method":"Co-immunoprecipitation, SPG7 processing assay, phosphorylation analysis of AFG3L2, cellular ATP and ROS measurements","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — direct processing assay with phosphorylation mechanism, multiple functional readouts","pmids":["24767997"],"is_preprint":false},{"year":2018,"finding":"AFG3L2 and YME1L cooperate in maintaining mitochondrial cristae morphogenesis, respiratory chain biogenesis, and OPA1 processing; loss of AFG3L2 specifically impairs complex IV assembly and function, whereas YME1L loss impairs complex I; double knockdown elevates short OPA1 forms and markedly reduces SPG7/paraplegin levels.","method":"AFG3L2 and YME1L siRNA knockdown in human cells, BN-PAGE for respiratory chain complexes, OPA1/OMA1 western blot, mitochondrial morphology analysis","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — clean KD with defined phenotypes but single lab","pmids":["30544562"],"is_preprint":false},{"year":2018,"finding":"AFG3L2 contains a specific substrate degron recognized within the presequence of mitochondrial ribosomal protein MrpL32; conserved residues in MrpL32's presequence target it for processing by AFG3L2. AFG3L2 cleaves peptide bonds with a strong preference for hydrophobic/small polar residues at the P1' position, as revealed by mass spectrometry-based peptidase specificity profiling.","method":"Solubilized AFG3L2 in vitro degradation assay, mass spectrometry of cleavage products, fluorogenic peptide substrates, mutagenesis of degron sequences","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with mutagenesis and MS-based specificity profiling","pmids":["29932645"],"is_preprint":false},{"year":2018,"finding":"Patient-derived SCA28 knock-in (M665Arg) MEFs show altered mitochondrial bioenergetics (decreased OCR, ATP synthesis, membrane potential) and greatly reduced expression of fusogenic OPA1 isoforms; pharmacological inhibition of mitochondrial protein translation with chloramphenicol reverses mitochondrial morphology defects, supporting mitochondrial proteotoxicity as the driver.","method":"Knock-in mouse model, Seahorse OCR measurement, OPA1 western blot, chloramphenicol rescue experiment, MEF mitochondrial morphology analysis","journal":"Neurobiology of disease","confidence":"Medium","confidence_rationale":"Tier 2 — knock-in model with pharmacological rescue, single lab","pmids":["30389403"],"is_preprint":false},{"year":2018,"finding":"A concurrent de novo AFG3L2 p.R468C mutation with heterozygous SPG7 deletion causes aberrant OPA1 processing and severe mitochondrial network fragmentation (not seen in SCA28 or SPG7 single-mutant cells); yeast functional assay confirmed pathogenicity of p.R468C.","method":"Patient fibroblast OPA1 processing assay, mitochondrial morphology imaging, yeast complementation","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — patient fibroblasts + yeast complementation, single case but multiple methods","pmids":["30252181"],"is_preprint":false},{"year":2019,"finding":"Cryo-EM structure of substrate-bound human AFG3L2 catalytic core reveals unique structural features including specialized pore-loop arrangements that integrate with conserved AAA+ motifs for ATP-dependent substrate translocation; disease mutations localize to these unique features and distinctly alter activity or stability.","method":"Cryo-electron microscopy, substrate-bound structure determination, functional mutagenesis of disease variants","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — cryo-EM structure with functional validation of disease mutations","pmids":["31327635"],"is_preprint":false},{"year":2019,"finding":"SCA28 patient fibroblasts with proteolytic-domain missense mutations show hyperactivated OMA1, which increases OPA1 processing and impairs mitochondrial fusion; altered mitochondrial proteostasis (excess misfolded proteins) is the trigger for OMA1 activation, and pharmacological attenuation of mitochondrial protein synthesis stabilizes OMA1 and long-form OPA1, rescuing fusion.","method":"SCA28 patient fibroblasts, CRISPR/Cas9 AFG3L2 KO HEK293T cells, Afg3l2−/− MEFs, OPA1/OMA1 western blot, mitochondrial morphology, Ca2+ uptake assay, chloramphenicol rescue","journal":"Journal of medical genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple patient lines + KO models + pharmacological rescue, orthogonal methods","pmids":["30910913"],"is_preprint":false},{"year":2020,"finding":"AFG3L2 mutations in the ATPase domain (distinct from SCA28 proteolytic-domain mutations) cause dominant optic atrophy by causing abnormal OPA1 processing with accumulation of short fission-inducing OPA1 forms and mitochondrial network fragmentation in patient fibroblasts; this mechanism was confirmed as distinct from SCA28-associated mutations in yeast assays.","method":"Patient fibroblast OPA1 processing assay, mitochondrial morphology quantification, yeast functional complementation assay","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 — patient fibroblasts + yeast, two orthogonal systems, multiple patient cases","pmids":["32219868"],"is_preprint":false},{"year":2020,"finding":"A novel AFG3L2 p.G337E mutation (near the AAA domain) strongly destabilizes long OPA1 isoforms via OMA1 hyperactivation and causes mitochondrial fragmentation in patient fibroblasts, revealing a third domain of AFG3L2 (intermembrane-space-proximal) relevant to OPA1 processing.","method":"Patient fibroblast OPA1 processing assay, OMA1 activation analysis, mitochondrial morphology imaging","journal":"Acta neuropathologica communications","confidence":"Medium","confidence_rationale":"Tier 2 — patient fibroblast functional analysis, single lab/family","pmids":["32600459"],"is_preprint":false},{"year":2023,"finding":"AFG3L2 is the mitochondrial m-AAA protease responsible for degrading SLC25A39 (a mitochondrial glutathione transporter) through recognition of SLC25A39's matrix loop 1; SLC25A39 protein stability is additionally regulated by mitochondrial iron-sulfur cluster sensing via four matrix cysteine residues, which inhibit AFG3L2-mediated degradation.","method":"Co-immunoprecipitation mass spectrometry, CRISPR KO in mammalian cells, mutational analysis of matrix loop 1 and cysteine residues, SLC25A39 stability assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1–2 — Co-IP MS identification plus CRISPR KO plus mutagenesis, multiple orthogonal methods","pmids":["38157846"],"is_preprint":false},{"year":2025,"finding":"AFG3L2 constitutively degrades VISA/MAVS under physiological conditions; physalin F binds to and activates AFG3L2, promoting MAVS degradation and suppressing RLR-mediated innate antiviral signaling; AFG3L2 knockdown enhances antiviral innate immune signaling.","method":"AFG3L2 knockdown, physalin F binding assay, MAVS degradation assay, in vivo mouse antiviral model","journal":"Pathogens","confidence":"Medium","confidence_rationale":"Tier 2 — knockdown plus pharmacological activation with substrate degradation assay, single lab","pmids":["41599057"],"is_preprint":false},{"year":2025,"finding":"AFG3L2 mediates degradation of MMADHC, a mitochondrial cobalamin trafficking protein; loss of Afg3l2 causes MMADHC accumulation, increased mitochondrial cobalamin conversion to adenosylcobalamin, hyperactivation of methylmalonyl-CoA mutase, and excessive succinyl-CoA production, impairing hematopoietic stem cell maintenance; Mmadhc knockdown partially rescues HSC defects in Afg3l2-deficient models.","method":"Afg3l2 KO mouse, metabolomics, MMADHC overexpression and knockdown rescue, HSC engraftment assay","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — KO mouse with substrate rescue experiment and metabolomic validation, multiple orthogonal methods","pmids":["41411131"],"is_preprint":false},{"year":2025,"finding":"AFG3L2 haploinsufficiency (50% reduction) in patient fibroblasts hyperactivates the stress-sensitive inner mitochondrial membrane protease OMA1, leading to increased OPA1 processing, mitochondrial shortening, and activation of the integrated stress response, causing axonal sensorimotor neuropathy.","method":"Patient fibroblast AFG3L2 protein quantification, OMA1/OPA1 western blot, mitochondrial morphology imaging, integrated stress response markers","journal":"Neurology. Genetics","confidence":"Medium","confidence_rationale":"Tier 2 — patient fibroblast functional assay with multiple molecular readouts, single case","pmids":["41883704"],"is_preprint":false},{"year":2025,"finding":"OMA1 cleaves the mitochondrial chaperone DNAJC15 and promotes its degradation by the m-AAA protease AFG3L2; loss of DNAJC15 reduces import of OXPHOS-related proteins via the TIMM23-TIMM17A translocase, limiting OXPHOS biogenesis under mitochondrial stress conditions.","method":"DNAJC15 degradation assay, OMA1 cleavage assay, AFG3L2 functional dependence, protein import assay with TIMM23/TIMM17A, OXPHOS biogenesis measurement","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays establishing substrate relationship, preprint not yet peer-reviewed","pmids":[],"is_preprint":true}],"current_model":"AFG3L2 is a mitochondrial inner-membrane AAA+ metalloprotease that forms homo-oligomeric complexes and hetero-oligomeric complexes with paraplegin (SPG7) to perform ATP-dependent protein quality control; its established substrates include MrpL32 (for mitoribosome maturation), SLC25A39 (regulated by iron-sulfur cluster sensing), MMADHC (regulating cobalamin flux), and VISA/MAVS (modulating antiviral signaling), and it processes OPA1 in an OMA1-dependent manner to regulate mitochondrial fusion—with disease mutations in the proteolytic domain causing proteotoxic stress that hyperactivates OMA1 and impairs fusion, while ATPase-domain mutations directly disrupt OPA1 processing, and overall loss of AFG3L2 impairs mitochondrial ribosome assembly, respiration, Ca²⁺ buffering, and axonal development."},"narrative":{"teleology":[{"year":1999,"claim":"Identification of AFG3L2 as a mitochondrial protein homologous to paraplegin and yeast m-AAA protease subunits established the gene as a candidate mitochondrial protease in mammals.","evidence":"Immunofluorescence and EST database screening in human cells","pmids":["10395799"],"confidence":"Medium","gaps":["No demonstration of proteolytic activity","No functional characterization beyond localization","Oligomeric state unknown"]},{"year":2008,"claim":"Demonstration that AFG3L2 forms both homo-oligomeric and hetero-oligomeric (with paraplegin) m-AAA complexes, and that its loss causes severe axonal developmental defects exceeding those of paraplegin loss, established AFG3L2 as the dominant functional subunit of the mammalian m-AAA protease.","evidence":"Afg3l2-null and missense knock-in mice compared with paraplegin-deficient mice; histology and electron microscopy","pmids":["18337413"],"confidence":"High","gaps":["Endogenous substrates unidentified","Mechanism of axonal degeneration unclear"]},{"year":2009,"claim":"Haploinsufficiency of Afg3l2 causing Purkinje cell dark degeneration with ROS elevation and respiratory chain dysfunction demonstrated that even partial loss of m-AAA protease activity is sufficient for neurodegeneration, establishing dose sensitivity.","evidence":"Afg3l2 heterozygous knockout mice; ROS measurements, electron microscopy, cerebellar assays","pmids":["19625515"],"confidence":"High","gaps":["Substrate accumulation not profiled","Whether ROS is cause or consequence unresolved"]},{"year":2010,"claim":"Linking heterozygous proteolytic-domain missense mutations to SCA28 and demonstrating respiratory and proteolytic deficiency in yeast reconstitution defined AFG3L2 as a disease gene and pinpointed the M41 peptidase domain as critical for function.","evidence":"Yeast complementation assay expressing human AFG3L2 mutants; respiratory growth and complex IV activity in five SCA28 families","pmids":["20208537"],"confidence":"High","gaps":["Mammalian substrates still unidentified","Mechanism connecting proteolytic deficiency to complex IV loss unclear"]},{"year":2011,"claim":"Characterization of a homozygous Y616C mutation revealed that disease severity correlates with oligomerization impairment, showing that complex assembly is a regulated step distinct from catalytic activity.","evidence":"Yeast complementation and blue native PAGE in patient fibroblasts","pmids":["22022284"],"confidence":"High","gaps":["Structural basis of oligomerization defect unknown","Effect on substrate spectrum not tested"]},{"year":2012,"claim":"Conditional Purkinje-cell knockout established that AFG3L2 is required cell-autonomously for mitoribosome assembly and mitochondrial translation, while AFG3L2-null MEFs revealed that mitochondrial fragmentation impairs ER–mitochondria Ca²⁺ transfer — rescued by OPA1 overexpression — linking protease loss to both translation and organelle dynamics.","evidence":"Purkinje-cell-specific Afg3l2 KO mouse with mitoribosome assembly and translation assays; Afg3l2−/− MEFs with Ca²⁺ imaging and OPA1 rescue","pmids":["23041622","22678058"],"confidence":"High","gaps":["How AFG3L2 promotes ribosome assembly (direct MrpL32 processing vs. indirect) not yet resolved at this point","OPA1 processing mechanism not delineated"]},{"year":2014,"claim":"Two advances clarified upstream regulation and downstream consequences: AFG3L2 tyrosine phosphorylation regulates SPG7 processing and complex activation, while in vivo rescue of ataxia by reducing mGluR1 signaling or glutamate levels placed AFG3L2 deficiency upstream of Ca²⁺ excitotoxicity in Purkinje cells.","evidence":"SPG7 processing and phosphorylation assays in cells; Afg3l2 haploinsufficient mice with genetic (mGluR1) and pharmacological (ceftriaxone) rescue","pmids":["24767997","25485680"],"confidence":"High","gaps":["Identity of kinase phosphorylating AFG3L2 unknown","Whether Ca²⁺ excitotoxicity is the sole degenerative pathway unresolved"]},{"year":2018,"claim":"In vitro reconstitution defined AFG3L2's peptidase specificity (hydrophobic/small polar P1' preference) and identified the MrpL32 presequence degron as the recognition element, while SCA28 knock-in MEFs showed that proteolytic-domain mutations cause proteotoxic stress that drives OPA1 loss — reversible by inhibiting mitochondrial translation with chloramphenicol.","evidence":"Purified AFG3L2 with MS-based cleavage profiling and MrpL32 degron mutagenesis; M665R knock-in MEFs with Seahorse, OPA1 blot, and chloramphenicol rescue","pmids":["29932645","30389403"],"confidence":"High","gaps":["Full substrate repertoire uncharacterized","Structural basis of degron recognition unknown at atomic level"]},{"year":2019,"claim":"The cryo-EM structure of substrate-engaged AFG3L2 revealed specialized pore-loop arrangements for ATP-dependent substrate translocation, and functional mapping showed that disease mutations cluster at these unique structural features — providing a structural framework for genotype-phenotype correlations. Separately, proteolytic-domain SCA28 mutations were shown to trigger OMA1 hyperactivation as the proximate cause of OPA1 clipping and fusion failure.","evidence":"Cryo-EM of substrate-bound AFG3L2 catalytic core with disease-variant mutagenesis; SCA28 patient fibroblasts, CRISPR KO cells, and MEFs with OMA1 analysis and chloramphenicol rescue","pmids":["31327635","30910913"],"confidence":"High","gaps":["Full-length complex structure with membrane domain not resolved","How proteotoxic stress activates OMA1 at a molecular level remains unclear"]},{"year":2020,"claim":"ATPase-domain mutations were shown to cause dominant optic atrophy through a mechanism distinct from SCA28: direct disruption of OPA1 processing rather than proteotoxicity-mediated OMA1 hyperactivation, establishing that different AFG3L2 domains produce distinct diseases through mechanistically separable pathways.","evidence":"Patient fibroblasts with ATPase-domain mutations; OPA1 processing and mitochondrial morphology compared to proteolytic-domain mutants; yeast complementation","pmids":["32219868","32600459"],"confidence":"High","gaps":["Whether AFG3L2 directly processes OPA1 or acts indirectly still debated","Tissue-specific vulnerability (retinal ganglion cells vs. Purkinje cells) unexplained"]},{"year":2023,"claim":"Identification of SLC25A39 as an AFG3L2 substrate whose degradation is gated by mitochondrial iron-sulfur cluster–dependent cysteine modification established AFG3L2 as a sensor-coupled quality control protease that integrates metabolite status with substrate turnover.","evidence":"Co-IP mass spectrometry, CRISPR KO, matrix loop 1 and cysteine mutagenesis, SLC25A39 stability assays in mammalian cells","pmids":["38157846"],"confidence":"High","gaps":["Whether other AFG3L2 substrates are similarly metabolite-gated is unknown","Structural basis of Fe-S cluster sensing not resolved"]},{"year":2025,"claim":"Expansion of the AFG3L2 substrate repertoire to include MMADHC (linking protease loss to cobalamin/succinyl-CoA dysregulation and hematopoietic stem cell failure) and MAVS (constitutive degradation controlling antiviral innate immunity) broadened AFG3L2's functional scope beyond neuronal and respiratory contexts to metabolism and immune signaling.","evidence":"Afg3l2 KO mouse with metabolomics and MMADHC knockdown rescue of HSC defects; AFG3L2 knockdown with MAVS degradation assay and in vivo antiviral model","pmids":["41411131","41599057"],"confidence":"High","gaps":["Comprehensive substrate profiling (degradomics) not yet performed","Physiological relevance of MAVS regulation by AFG3L2 in human immune cells untested","MMADHC degradation mechanism (degron, cofactor dependence) uncharacterized"]},{"year":null,"claim":"Key unresolved questions include the complete substrate repertoire of AFG3L2, the molecular mechanism by which proteotoxic stress activates OMA1, whether AFG3L2 directly cleaves OPA1, and the structural and regulatory basis for tissue-specific vulnerability (Purkinje cells vs. retinal ganglion cells vs. HSCs) in different AFG3L2-linked diseases.","evidence":"","pmids":[],"confidence":"Low","gaps":["No comprehensive degradomics performed","OMA1 activation mechanism at molecular level unknown","Full-length membrane-embedded AFG3L2 complex structure unavailable","Tissue-specific cofactors or regulators not identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3,10,13,14,17,19]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[13,15]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[3,10]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[0,1,5,6]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[5,10,14,17,19]},{"term_id":"R-HSA-1852241","term_label":"Organelle biogenesis and maintenance","supporting_discovery_ids":[5,6,9]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[17,19]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,15,20]}],"complexes":["m-AAA protease homo-oligomeric complex","m-AAA protease hetero-oligomeric complex (AFG3L2/SPG7)"],"partners":["SPG7","OMA1","OPA1","MRPL32","SLC25A39","MMADHC","MAVS","DNAJC15"],"other_free_text":[]},"mechanistic_narrative":"AFG3L2 is a mitochondrial inner-membrane AAA+ metalloprotease that serves as a central hub for mitochondrial protein quality control, ribosome biogenesis, cristae maintenance, and metabolite homeostasis. It forms homo-oligomeric complexes and hetero-oligomeric complexes with paraplegin (SPG7), processing substrates including MrpL32 (mitoribosome maturation), SLC25A39 (glutathione transport regulated by iron-sulfur cluster sensing), MMADHC (cobalamin trafficking), and MAVS (innate immune signaling), with substrate recognition driven by specific degron sequences and a preference for hydrophobic/small polar residues at the P1' cleavage position [PMID:29932645, PMID:38157846, PMID:41411131, PMID:41599057]. Loss of AFG3L2 proteolytic activity triggers mitochondrial proteotoxic stress that hyperactivates the stress protease OMA1, leading to excessive OPA1 cleavage, mitochondrial fragmentation, impaired Ca²⁺ buffering, and activation of the integrated stress response, whereas ATPase-domain mutations directly disrupt OPA1 processing through a mechanistically distinct pathway [PMID:30910913, PMID:32219868, PMID:41883704]. Heterozygous mutations in AFG3L2 cause spinocerebellar ataxia type 28 (SCA28) and dominant optic atrophy, with Purkinje cell degeneration driven by respiratory chain dysfunction and glutamate-mediated Ca²⁺ excitotoxicity [PMID:20208537, PMID:25485680, PMID:32219868]."},"prefetch_data":{"uniprot":{"accession":"Q9Y4W6","full_name":"Mitochondrial inner membrane m-AAA protease component AFG3L2","aliases":["AFG3-like protein 2","Paraplegin-like protein"],"length_aa":797,"mass_kda":88.6,"function":"Catalytic component of the m-AAA protease, a protease that plays a key role in proteostasis of inner mitochondrial membrane proteins, and which is essential for axonal and neuron development (PubMed:19748354, PubMed:28396416, PubMed:29932645, PubMed:30683687, PubMed:31327635, PubMed:37917749, PubMed:38157846). AFG3L2 possesses both ATPase and protease activities: the ATPase activity is required to unfold substrates, threading them into the internal proteolytic cavity for hydrolysis into small peptide fragments (PubMed:19748354, PubMed:31327635). The m-AAA protease carries out quality control in the inner membrane of the mitochondria by mediating degradation of mistranslated or misfolded polypeptides (PubMed:26504172, PubMed:30683687, PubMed:34718584). The m-AAA protease complex also promotes the processing and maturation of mitochondrial proteins, such as MRPL32/bL32m, PINK1 and SP7 (PubMed:22354088, PubMed:29932645, PubMed:30252181). Mediates protein maturation of the mitochondrial ribosomal subunit MRPL32/bL32m by catalyzing the cleavage of the presequence of MRPL32/bL32m prior to assembly into the mitochondrial ribosome (PubMed:29932645). Required for SPG7 maturation into its active mature form after SPG7 cleavage by mitochondrial-processing peptidase (MPP) (PubMed:30252181). Required for the maturation of PINK1 into its 52kDa mature form after its cleavage by mitochondrial-processing peptidase (MPP) (PubMed:22354088). Acts as a regulator of calcium in neurons by mediating degradation of SMDT1/EMRE before its assembly with the uniporter complex, limiting the availability of SMDT1/EMRE for MCU assembly and promoting efficient assembly of gatekeeper subunits with MCU (PubMed:27642048, PubMed:28396416). Promotes the proteolytic degradation of GHITM upon hyperpolarization of mitochondria: progressive GHITM degradation leads to respiratory complex I degradation and broad reshaping of the mitochondrial proteome by AFG3L2 (PubMed:35912435). Also acts as a regulator of mitochondrial glutathione homeostasis by mediating cleavage and degradation of SLC25A39 (PubMed:37917749, PubMed:38157846). SLC25A39 cleavage is prevented when SLC25A39 binds iron-sulfur (PubMed:37917749, PubMed:38157846). Involved in the regulation of OMA1-dependent processing of OPA1 (PubMed:17615298, PubMed:29545505, PubMed:30252181, PubMed:30683687, PubMed:32600459). May act by mediating processing of OMA1 precursor, participating in OMA1 maturation (PubMed:29545505)","subcellular_location":"Mitochondrion inner membrane","url":"https://www.uniprot.org/uniprotkb/Q9Y4W6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/AFG3L2","classification":"Common Essential","n_dependent_lines":1177,"n_total_lines":1208,"dependency_fraction":0.9743377483443708},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AFG3L2","total_profiled":1310},"omim":[{"mim_id":"618977","title":"OPTIC ATROPHY 12; OPA12","url":"https://www.omim.org/entry/618977"},{"mim_id":"617267","title":"MATRIX AAA PEPTIDASE-INTERACTING PROTEIN 1; MAIP1","url":"https://www.omim.org/entry/617267"},{"mim_id":"615898","title":"NADH DEHYDROGENASE (UBIQUINONE) COMPLEX I, ASSEMBLY FACTOR 7; NDUFAF7","url":"https://www.omim.org/entry/615898"},{"mim_id":"615588","title":"SINGLE-PASS MEMBRANE PROTEIN WITH ASPARTATE-RICH TAIL 1; SMDT1","url":"https://www.omim.org/entry/615588"},{"mim_id":"614487","title":"SPASTIC ATAXIA 5, AUTOSOMAL RECESSIVE; SPAX5","url":"https://www.omim.org/entry/614487"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Mitochondria","reliability":"Enhanced"},{"location":"Perinuclear theca","reliability":"Additional"},{"location":"Calyx","reliability":"Additional"},{"location":"Connecting piece","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"Principal piece","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"skeletal muscle","ntpm":96.6},{"tissue":"tongue","ntpm":92.6}],"url":"https://www.proteinatlas.org/search/AFG3L2"},"hgnc":{"alias_symbol":["SPAX5"],"prev_symbol":["SCA28"]},"alphafold":{"accession":"Q9Y4W6","domains":[{"cath_id":"3.40.1690.20","chopping":"146-268","consensus_level":"medium","plddt":79.8761,"start":146,"end":268},{"cath_id":"3.40.50.300","chopping":"298-475","consensus_level":"high","plddt":87.1812,"start":298,"end":475},{"cath_id":"1.10.8.60","chopping":"481-555","consensus_level":"high","plddt":93.7904,"start":481,"end":555},{"cath_id":"1.20.58.760","chopping":"566-680_690-760","consensus_level":"high","plddt":92.7572,"start":566,"end":760}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y4W6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y4W6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9Y4W6-F1-predicted_aligned_error_v6.png","plddt_mean":76.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AFG3L2","jax_strain_url":"https://www.jax.org/strain/search?query=AFG3L2"},"sequence":{"accession":"Q9Y4W6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9Y4W6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9Y4W6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9Y4W6"}},"corpus_meta":[{"pmid":"20208537","id":"PMC_20208537","title":"Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28.","date":"2010","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20208537","citation_count":255,"is_preprint":false},{"pmid":"22022284","id":"PMC_22022284","title":"Whole-exome sequencing identifies homozygous AFG3L2 mutations in a spastic ataxia-neuropathy syndrome linked to mitochondrial m-AAA proteases.","date":"2011","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22022284","citation_count":178,"is_preprint":false},{"pmid":"16251216","id":"PMC_16251216","title":"SCA28, a novel form of autosomal dominant cerebellar ataxia on chromosome 18p11.22-q11.2.","date":"2005","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16251216","citation_count":91,"is_preprint":false},{"pmid":"18337413","id":"PMC_18337413","title":"The mitochondrial protease AFG3L2 is essential for axonal development.","date":"2008","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18337413","citation_count":90,"is_preprint":false},{"pmid":"23041622","id":"PMC_23041622","title":"AFG3L2 supports mitochondrial protein synthesis and Purkinje cell survival.","date":"2012","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/23041622","citation_count":89,"is_preprint":false},{"pmid":"19625515","id":"PMC_19625515","title":"Haploinsufficiency of AFG3L2, the gene responsible for spinocerebellar ataxia type 28, causes mitochondria-mediated Purkinje cell dark degeneration.","date":"2009","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19625515","citation_count":84,"is_preprint":false},{"pmid":"31327635","id":"PMC_31327635","title":"Unique Structural Features of the Mitochondrial AAA+ Protease AFG3L2 Reveal the Molecular Basis for Activity in Health and Disease.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31327635","citation_count":75,"is_preprint":false},{"pmid":"10395799","id":"PMC_10395799","title":"Identification and characterization of AFG3L2, a novel paraplegin-related gene.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10395799","citation_count":69,"is_preprint":false},{"pmid":"25485680","id":"PMC_25485680","title":"Purkinje neuron Ca2+ influx reduction rescues ataxia in SCA28 model.","date":"2014","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25485680","citation_count":69,"is_preprint":false},{"pmid":"20725928","id":"PMC_20725928","title":"Missense mutations in the AFG3L2 proteolytic domain account for ∼1.5% of European autosomal dominant cerebellar ataxias.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20725928","citation_count":65,"is_preprint":false},{"pmid":"22678058","id":"PMC_22678058","title":"Respiratory dysfunction by AFG3L2 deficiency causes decreased mitochondrial calcium uptake via organellar network fragmentation.","date":"2012","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22678058","citation_count":45,"is_preprint":false},{"pmid":"32219868","id":"PMC_32219868","title":"ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy.","date":"2020","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32219868","citation_count":41,"is_preprint":false},{"pmid":"20354562","id":"PMC_20354562","title":"Early onset and slow progression of SCA28, a rare dominant ataxia in a large four-generation family with a novel AFG3L2 mutation.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20354562","citation_count":41,"is_preprint":false},{"pmid":"32548275","id":"PMC_32548275","title":"Mutations in the m-AAA proteases AFG3L2 and SPG7 are causing isolated dominant optic atrophy.","date":"2020","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32548275","citation_count":37,"is_preprint":false},{"pmid":"26539208","id":"PMC_26539208","title":"A novel mutation of AFG3L2 might cause dominant optic atrophy in patients with mild intellectual disability.","date":"2015","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/26539208","citation_count":36,"is_preprint":false},{"pmid":"38157846","id":"PMC_38157846","title":"Dual regulation of SLC25A39 by AFG3L2 and iron controls mitochondrial glutathione homeostasis.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/38157846","citation_count":35,"is_preprint":false},{"pmid":"24767997","id":"PMC_24767997","title":"SPG7 variant escapes phosphorylation-regulated processing by AFG3L2, elevates mitochondrial ROS, and is associated with multiple clinical phenotypes.","date":"2014","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24767997","citation_count":33,"is_preprint":false},{"pmid":"30252181","id":"PMC_30252181","title":"Concurrent AFG3L2 and SPG7 mutations associated with syndromic parkinsonism and optic atrophy with aberrant OPA1 processing and mitochondrial network fragmentation.","date":"2018","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/30252181","citation_count":33,"is_preprint":false},{"pmid":"30544562","id":"PMC_30544562","title":"Loss of Mitochondrial AAA Proteases AFG3L2 and YME1L Impairs Mitochondrial Structure and Respiratory Chain Biogenesis.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30544562","citation_count":28,"is_preprint":false},{"pmid":"30389403","id":"PMC_30389403","title":"Mice harbouring a SCA28 patient mutation in AFG3L2 develop late-onset ataxia associated with enhanced mitochondrial proteotoxicity.","date":"2018","source":"Neurobiology of disease","url":"https://pubmed.ncbi.nlm.nih.gov/30389403","citation_count":24,"is_preprint":false},{"pmid":"30910913","id":"PMC_30910913","title":"Pathogenic variants in the AFG3L2 proteolytic domain cause SCA28 through haploinsufficiency and proteostatic stress-driven OMA1 activation.","date":"2019","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30910913","citation_count":24,"is_preprint":false},{"pmid":"20426821","id":"PMC_20426821","title":"Mouse brain expression patterns of Spg7, Afg3l1, and Afg3l2 transcripts, encoding for the mitochondrial m-AAA protease.","date":"2010","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/20426821","citation_count":24,"is_preprint":false},{"pmid":"24814845","id":"PMC_24814845","title":"Partial deletion of AFG3L2 causing spinocerebellar ataxia type 28.","date":"2014","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24814845","citation_count":22,"is_preprint":false},{"pmid":"28449981","id":"PMC_28449981","title":"Recessive AFG3L2 Mutation Causes Progressive Microcephaly, Early Onset Seizures, Spasticity, and Basal Ganglia Involvement.","date":"2017","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/28449981","citation_count":21,"is_preprint":false},{"pmid":"32237276","id":"PMC_32237276","title":"Expanding the clinical and genetic heterogeneity of SPAX5.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/32237276","citation_count":20,"is_preprint":false},{"pmid":"24293060","id":"PMC_24293060","title":"A novel missense mutation in AFG3L2 associated with late onset and slow progression of spinocerebellar ataxia type 28.","date":"2013","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/24293060","citation_count":20,"is_preprint":false},{"pmid":"26677414","id":"PMC_26677414","title":"Spinocerebellar ataxia 28: a novel AFG3L2 mutation in a German family with young onset, slow progression and saccadic slowing.","date":"2015","source":"Cerebellum & ataxias","url":"https://pubmed.ncbi.nlm.nih.gov/26677414","citation_count":18,"is_preprint":false},{"pmid":"29932645","id":"PMC_29932645","title":"Dissecting Substrate Specificities of the Mitochondrial AFG3L2 Protease.","date":"2018","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29932645","citation_count":17,"is_preprint":false},{"pmid":"24272953","id":"PMC_24272953","title":"A novel frameshift mutation in the AFG3L2 gene in a patient with spinocerebellar ataxia.","date":"2014","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/24272953","citation_count":16,"is_preprint":false},{"pmid":"32600459","id":"PMC_32600459","title":"A novel AFG3L2 mutation close to AAA domain leads to aberrant OMA1 and OPA1 processing in a family with optic atrophy.","date":"2020","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/32600459","citation_count":16,"is_preprint":false},{"pmid":"31111429","id":"PMC_31111429","title":"Spinocerebellar Ataxia Type 28-Phenotypic and Molecular Characterization of a Family with Heterozygous and Compound-Heterozygous Mutations in AFG3L2.","date":"2019","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/31111429","citation_count":15,"is_preprint":false},{"pmid":"26868664","id":"PMC_26868664","title":"SCA28: Novel Mutation in the AFG3L2 Proteolytic Domain Causes a Mild Cerebellar Syndrome with Selective Type-1 Muscle Fiber Atrophy.","date":"2017","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/26868664","citation_count":14,"is_preprint":false},{"pmid":"23777634","id":"PMC_23777634","title":"Genome-wide expression profiling and functional characterization of SCA28 lymphoblastoid cell lines reveal impairment in cell growth and activation of apoptotic pathways.","date":"2013","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/23777634","citation_count":13,"is_preprint":false},{"pmid":"25927548","id":"PMC_25927548","title":"An atypical form of AOA2 with myoclonus associated with mutations in SETX and AFG3L2.","date":"2015","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25927548","citation_count":12,"is_preprint":false},{"pmid":"34333379","id":"PMC_34333379","title":"Expanding the phenotype of AFG3L2 mutations: Late-onset autosomal recessive spinocerebellar ataxia.","date":"2021","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34333379","citation_count":10,"is_preprint":false},{"pmid":"31781336","id":"PMC_31781336","title":"Upregulation of Peroxiredoxin 3 Protects Afg3l2-KO Cortical Neurons In Vitro from Oxidative Stress: A Paradigm for Neuronal Cell Survival under Neurodegenerative Conditions.","date":"2019","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/31781336","citation_count":9,"is_preprint":false},{"pmid":"36786711","id":"PMC_36786711","title":"Netrin-1 attenuates cerebral ischemia/reperfusion injury by limiting mitochondrial ROS and Ca2+ levels via activation of AKT phosphorylation and mitochondrial m-AAA protease AFG3L2.","date":"2023","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/36786711","citation_count":8,"is_preprint":false},{"pmid":"35970831","id":"PMC_35970831","title":"A novel mutation located in the intermembrane space domain of AFG3L2 causes dominant optic atrophy through decreasing the stability of the encoded protein.","date":"2022","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/35970831","citation_count":6,"is_preprint":false},{"pmid":"22563911","id":"PMC_22563911","title":"Spinocerebellar ataxia type 28 (SCA28) is an uncommon cause of dominant ataxia among Chinese kindreds.","date":"2012","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22563911","citation_count":5,"is_preprint":false},{"pmid":"39428429","id":"PMC_39428429","title":"Compound heterozygous mutation of AFG3L2 causes autosomal recessive spinocerebellar ataxia through mitochondrial impairment and MICU1 mediated Ca2+ overload.","date":"2024","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39428429","citation_count":4,"is_preprint":false},{"pmid":"37025825","id":"PMC_37025825","title":"Novel compound heterozygous mutations in the AFG3L2 gene in a Chinese child with microcephaly, early-onset seizures, and cerebral atrophy.","date":"2023","source":"Heliyon","url":"https://pubmed.ncbi.nlm.nih.gov/37025825","citation_count":3,"is_preprint":false},{"pmid":"40305785","id":"PMC_40305785","title":"Dual Role of CRABP2 in Colorectal Cancer: Oncogenesis via Nuclear RB1 and Cytoplasmic AFG3L2/SLC25A39 Axis, While Limiting Liver Metastasis through Cytoplasmic AFG3L2/PINK1/Parkin-Mediated Mitophagy.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40305785","citation_count":3,"is_preprint":false},{"pmid":"40451320","id":"PMC_40451320","title":"Mitochondrial Protease AFG3L2 Inhibits Ferroptosis of Intestinal Epithelial Cells through PPARA/GPX4 Signaling Pathway to Improve Experimental Enteritis.","date":"2025","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/40451320","citation_count":2,"is_preprint":false},{"pmid":"40993178","id":"PMC_40993178","title":"SLC25A39 overexpression exacerbates lung adenocarcinoma progression and is negatively regulated by AFG3L2.","date":"2025","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40993178","citation_count":1,"is_preprint":false},{"pmid":"38278202","id":"PMC_38278202","title":"AFG3L2 and ACO2-Linked Dominant Optic Atrophy: Genotype-Phenotype Characterization Compared to OPA1 Patients.","date":"2024","source":"American journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/38278202","citation_count":1,"is_preprint":false},{"pmid":"36974169","id":"PMC_36974169","title":"Identification of AFG3L2 dominant optic atrophy following reanalysis of clinical exome sequencing.","date":"2023","source":"American journal of ophthalmology case reports","url":"https://pubmed.ncbi.nlm.nih.gov/36974169","citation_count":1,"is_preprint":false},{"pmid":"36447112","id":"PMC_36447112","title":"AFG3L2 Biallelic Mutation: Clinical Heterogeneity in Two Italian Patients.","date":"2022","source":"Cerebellum (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36447112","citation_count":1,"is_preprint":false},{"pmid":"41411131","id":"PMC_41411131","title":"Afg3l2 couples mitochondrial vitamin B12 trafficking to amino acid metabolism to safeguard hematopoietic stem cell homeostasis.","date":"2025","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41411131","citation_count":1,"is_preprint":false},{"pmid":"40051915","id":"PMC_40051915","title":"Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegeneration in spastic ataxia type 5.","date":"2025","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/40051915","citation_count":0,"is_preprint":false},{"pmid":"41883704","id":"PMC_41883704","title":"Expanding the AFG3L2 Spectrum: A Link to Axonal Neuropathy.","date":"2026","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/41883704","citation_count":0,"is_preprint":false},{"pmid":"40260968","id":"PMC_40260968","title":"Biallelic Variants in AFG3L2 Causing Spastic Ataxia Type 5 (SPAX5): Report of Two Pediatric Cases from Bogotá, Colombia.","date":"2025","source":"Movement disorders clinical practice","url":"https://pubmed.ncbi.nlm.nih.gov/40260968","citation_count":0,"is_preprint":false},{"pmid":"39564550","id":"PMC_39564550","title":"Optic Neuropathy AFG3L2 Related in a Patient Affected by Congenital Stationary Night Blindness.","date":"2024","source":"Case reports in ophthalmological medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39564550","citation_count":0,"is_preprint":false},{"pmid":"16130464","id":"PMC_16130464","title":"Bovine spinal muscular atrophy: AFG3L2 is not a positional candidate gene.","date":"2005","source":"Journal of animal breeding and genetics = Zeitschrift fur Tierzuchtung und Zuchtungsbiologie","url":"https://pubmed.ncbi.nlm.nih.gov/16130464","citation_count":0,"is_preprint":false},{"pmid":"41599057","id":"PMC_41599057","title":"Physalin F Promotes AFG3L2-Mediated Degradation of VISA/MAVS to Suppress Innate Immune Response to RNA Virus.","date":"2026","source":"Pathogens (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41599057","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.05.24312261","title":"Digenic inheritance of mutations in <i>SPG7</i> and <i>AFG3L2</i> causes motor neuron and cerebellar disorders","date":"2025-07-08","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.05.24312261","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.09.687409","title":"A BCG toxic effector induces mitochondrial DNA compaction to refrain protective immunity","date":"2025-11-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.09.687409","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.04.641455","title":"Stress adaptation of mitochondrial protein import by OMA1-mediated degradation of DNAJC15","date":"2025-03-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.04.641455","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":28473,"output_tokens":5213,"usd":0.081807},"stage2":{"model":"claude-opus-4-6","input_tokens":8760,"output_tokens":3520,"usd":0.1977},"total_usd":0.279507,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"AFG3L2 encodes a 797-amino-acid mitochondrial protein homologous to paraplegin and yeast Afg3p/Rca1p, localizes to the mitochondrial compartment, and maps to chromosome 18p11; immunofluorescence established its mitochondrial subcellular localization.\",\n      \"method\": \"Immunofluorescence, EST database screening, radiation hybrid mapping\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiment; single lab, moderate methods\",\n      \"pmids\": [\"10395799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AFG3L2 assembles with paraplegin into a hetero-oligomeric m-AAA protease complex in the inner mitochondrial membrane and also forms homo-oligomeric complexes; loss of AFG3L2 in mice causes impaired axonal development with delayed myelination and poor radial axonal growth, whereas paraplegin loss causes only mild late-onset axonal degeneration, explained by AFG3L2's higher neuronal expression and ability to support both homo- and hetero-oligomerization.\",\n      \"method\": \"Afg3l2 null and missense knock-in mouse models, histology, electron microscopy, functional comparisons with paraplegin-deficient mice\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — two independent murine genetic models with defined cellular phenotypes, replicated mechanistic interpretation\",\n      \"pmids\": [\"18337413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Haploinsufficiency of Afg3l2 in mice causes respiratory chain dysfunction, increased reactive oxygen species production, and dark degeneration of Purkinje cells, establishing that a 50% reduction in m-AAA protease activity is sufficient to trigger mitochondria-mediated cerebellar neurodegeneration.\",\n      \"method\": \"Afg3l2 heterozygous mouse model, ROS measurements, electron microscopy, cerebellar functional assays\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO/haploinsufficient model with defined cellular phenotype and multiple orthogonal readouts\",\n      \"pmids\": [\"19625515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Heterozygous missense mutations in AFG3L2 (in its proteolytic/M41 peptidase domain) cause SCA28; m-AAA-deficient yeast expressing mutant human AFG3L2 homocomplex show respiratory deficiency, proteolytic impairment, and respiratory chain complex IV deficiency, confirming the proteolytic domain is critical for substrate handling.\",\n      \"method\": \"Yeast complementation assay, respiratory growth assays, complex IV activity measurement, homology modeling\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — yeast reconstitution with mutagenesis, multiple functional readouts, replicated across five families\",\n      \"pmids\": [\"20208537\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"A homozygous AFG3L2 Y616C mutation causes a hypomorphic variant with oligomerization defects: AFG3L2(Y616C) complexes form impaired homo-oligomers and, to a greater extent, impaired hetero-oligomers with paraplegin, as demonstrated in yeast and patient fibroblasts.\",\n      \"method\": \"Yeast complementation assay, blue native PAGE in patient fibroblasts, oligomerization analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — yeast functional assay plus patient fibroblast native gel analysis, two orthogonal systems\",\n      \"pmids\": [\"22022284\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"AFG3L2 is required for mitochondrial ribosome assembly and mitochondrial protein synthesis in Purkinje cells; conditional Afg3l2 knockout in Purkinje cells causes cell-autonomous neurodegeneration preceded by mitochondrial network fragmentation and defects in mitochondrially encoded respiratory chain subunits.\",\n      \"method\": \"Conditional Purkinje-cell-specific Afg3l2 knockout mouse, constitutive knockout, mitochondrial translation assay, mitoribosome assembly analysis, live imaging of mitochondrial morphology\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — conditional KO with defined cellular phenotype, multiple orthogonal methods including ribosome assembly and translation assays\",\n      \"pmids\": [\"23041622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Loss of AFG3L2 in mouse embryonic fibroblasts causes mitochondrial network fragmentation secondary to respiratory dysfunction and consequent OPA1 processing, which reduces mitochondrial Ca2+ uptake capacity by leaving a subset of mitochondria disconnected from the ER; OPA1 overexpression rescues Ca2+ buffering but not respiration.\",\n      \"method\": \"Afg3l2−/− MEFs, Ca2+ imaging, permeabilized-cell Ca2+ uptake assay, OPA1 overexpression rescue, mitochondrial morphology analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO MEFs with multiple orthogonal methods, rescue experiment with OPA1\",\n      \"pmids\": [\"22678058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"AFG3L2-deficient Purkinje cells have impaired mitochondrial Ca2+ buffering due to mitochondrial depolarization and altered organelle trafficking to dendrites; partial genetic silencing of mGluR1 or ceftriaxone-mediated reduction of glutamate stimulation reduces Ca2+ influx and rescues ataxia in SCA28 mice, placing AFG3L2 upstream of the Ca2+ excitotoxicity pathway.\",\n      \"method\": \"Afg3l2 haploinsufficient mouse, Ca2+ imaging in cultured Purkinje cells, mGluR1 genetic silencing, ceftriaxone pharmacological treatment, behavioral assays\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via genetic and pharmacological rescue in vivo and in vitro, multiple orthogonal approaches\",\n      \"pmids\": [\"25485680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SPG7 processing (cleavage and activation) upon assembly into the m-AAA complex requires AFG3L2 and is regulated by tyrosine phosphorylation of AFG3L2; a SPG7 Q688 variant bypasses this phosphorylation-dependent regulation, constitutively activating the complex and elevating ROS and ATP production.\",\n      \"method\": \"Co-immunoprecipitation, SPG7 processing assay, phosphorylation analysis of AFG3L2, cellular ATP and ROS measurements\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct processing assay with phosphorylation mechanism, multiple functional readouts\",\n      \"pmids\": [\"24767997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AFG3L2 and YME1L cooperate in maintaining mitochondrial cristae morphogenesis, respiratory chain biogenesis, and OPA1 processing; loss of AFG3L2 specifically impairs complex IV assembly and function, whereas YME1L loss impairs complex I; double knockdown elevates short OPA1 forms and markedly reduces SPG7/paraplegin levels.\",\n      \"method\": \"AFG3L2 and YME1L siRNA knockdown in human cells, BN-PAGE for respiratory chain complexes, OPA1/OMA1 western blot, mitochondrial morphology analysis\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean KD with defined phenotypes but single lab\",\n      \"pmids\": [\"30544562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AFG3L2 contains a specific substrate degron recognized within the presequence of mitochondrial ribosomal protein MrpL32; conserved residues in MrpL32's presequence target it for processing by AFG3L2. AFG3L2 cleaves peptide bonds with a strong preference for hydrophobic/small polar residues at the P1' position, as revealed by mass spectrometry-based peptidase specificity profiling.\",\n      \"method\": \"Solubilized AFG3L2 in vitro degradation assay, mass spectrometry of cleavage products, fluorogenic peptide substrates, mutagenesis of degron sequences\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with mutagenesis and MS-based specificity profiling\",\n      \"pmids\": [\"29932645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Patient-derived SCA28 knock-in (M665Arg) MEFs show altered mitochondrial bioenergetics (decreased OCR, ATP synthesis, membrane potential) and greatly reduced expression of fusogenic OPA1 isoforms; pharmacological inhibition of mitochondrial protein translation with chloramphenicol reverses mitochondrial morphology defects, supporting mitochondrial proteotoxicity as the driver.\",\n      \"method\": \"Knock-in mouse model, Seahorse OCR measurement, OPA1 western blot, chloramphenicol rescue experiment, MEF mitochondrial morphology analysis\",\n      \"journal\": \"Neurobiology of disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knock-in model with pharmacological rescue, single lab\",\n      \"pmids\": [\"30389403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A concurrent de novo AFG3L2 p.R468C mutation with heterozygous SPG7 deletion causes aberrant OPA1 processing and severe mitochondrial network fragmentation (not seen in SCA28 or SPG7 single-mutant cells); yeast functional assay confirmed pathogenicity of p.R468C.\",\n      \"method\": \"Patient fibroblast OPA1 processing assay, mitochondrial morphology imaging, yeast complementation\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — patient fibroblasts + yeast complementation, single case but multiple methods\",\n      \"pmids\": [\"30252181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Cryo-EM structure of substrate-bound human AFG3L2 catalytic core reveals unique structural features including specialized pore-loop arrangements that integrate with conserved AAA+ motifs for ATP-dependent substrate translocation; disease mutations localize to these unique features and distinctly alter activity or stability.\",\n      \"method\": \"Cryo-electron microscopy, substrate-bound structure determination, functional mutagenesis of disease variants\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — cryo-EM structure with functional validation of disease mutations\",\n      \"pmids\": [\"31327635\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SCA28 patient fibroblasts with proteolytic-domain missense mutations show hyperactivated OMA1, which increases OPA1 processing and impairs mitochondrial fusion; altered mitochondrial proteostasis (excess misfolded proteins) is the trigger for OMA1 activation, and pharmacological attenuation of mitochondrial protein synthesis stabilizes OMA1 and long-form OPA1, rescuing fusion.\",\n      \"method\": \"SCA28 patient fibroblasts, CRISPR/Cas9 AFG3L2 KO HEK293T cells, Afg3l2−/− MEFs, OPA1/OMA1 western blot, mitochondrial morphology, Ca2+ uptake assay, chloramphenicol rescue\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple patient lines + KO models + pharmacological rescue, orthogonal methods\",\n      \"pmids\": [\"30910913\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"AFG3L2 mutations in the ATPase domain (distinct from SCA28 proteolytic-domain mutations) cause dominant optic atrophy by causing abnormal OPA1 processing with accumulation of short fission-inducing OPA1 forms and mitochondrial network fragmentation in patient fibroblasts; this mechanism was confirmed as distinct from SCA28-associated mutations in yeast assays.\",\n      \"method\": \"Patient fibroblast OPA1 processing assay, mitochondrial morphology quantification, yeast functional complementation assay\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient fibroblasts + yeast, two orthogonal systems, multiple patient cases\",\n      \"pmids\": [\"32219868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A novel AFG3L2 p.G337E mutation (near the AAA domain) strongly destabilizes long OPA1 isoforms via OMA1 hyperactivation and causes mitochondrial fragmentation in patient fibroblasts, revealing a third domain of AFG3L2 (intermembrane-space-proximal) relevant to OPA1 processing.\",\n      \"method\": \"Patient fibroblast OPA1 processing assay, OMA1 activation analysis, mitochondrial morphology imaging\",\n      \"journal\": \"Acta neuropathologica communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — patient fibroblast functional analysis, single lab/family\",\n      \"pmids\": [\"32600459\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AFG3L2 is the mitochondrial m-AAA protease responsible for degrading SLC25A39 (a mitochondrial glutathione transporter) through recognition of SLC25A39's matrix loop 1; SLC25A39 protein stability is additionally regulated by mitochondrial iron-sulfur cluster sensing via four matrix cysteine residues, which inhibit AFG3L2-mediated degradation.\",\n      \"method\": \"Co-immunoprecipitation mass spectrometry, CRISPR KO in mammalian cells, mutational analysis of matrix loop 1 and cysteine residues, SLC25A39 stability assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — Co-IP MS identification plus CRISPR KO plus mutagenesis, multiple orthogonal methods\",\n      \"pmids\": [\"38157846\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AFG3L2 constitutively degrades VISA/MAVS under physiological conditions; physalin F binds to and activates AFG3L2, promoting MAVS degradation and suppressing RLR-mediated innate antiviral signaling; AFG3L2 knockdown enhances antiviral innate immune signaling.\",\n      \"method\": \"AFG3L2 knockdown, physalin F binding assay, MAVS degradation assay, in vivo mouse antiviral model\",\n      \"journal\": \"Pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockdown plus pharmacological activation with substrate degradation assay, single lab\",\n      \"pmids\": [\"41599057\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AFG3L2 mediates degradation of MMADHC, a mitochondrial cobalamin trafficking protein; loss of Afg3l2 causes MMADHC accumulation, increased mitochondrial cobalamin conversion to adenosylcobalamin, hyperactivation of methylmalonyl-CoA mutase, and excessive succinyl-CoA production, impairing hematopoietic stem cell maintenance; Mmadhc knockdown partially rescues HSC defects in Afg3l2-deficient models.\",\n      \"method\": \"Afg3l2 KO mouse, metabolomics, MMADHC overexpression and knockdown rescue, HSC engraftment assay\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with substrate rescue experiment and metabolomic validation, multiple orthogonal methods\",\n      \"pmids\": [\"41411131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"AFG3L2 haploinsufficiency (50% reduction) in patient fibroblasts hyperactivates the stress-sensitive inner mitochondrial membrane protease OMA1, leading to increased OPA1 processing, mitochondrial shortening, and activation of the integrated stress response, causing axonal sensorimotor neuropathy.\",\n      \"method\": \"Patient fibroblast AFG3L2 protein quantification, OMA1/OPA1 western blot, mitochondrial morphology imaging, integrated stress response markers\",\n      \"journal\": \"Neurology. Genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — patient fibroblast functional assay with multiple molecular readouts, single case\",\n      \"pmids\": [\"41883704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"OMA1 cleaves the mitochondrial chaperone DNAJC15 and promotes its degradation by the m-AAA protease AFG3L2; loss of DNAJC15 reduces import of OXPHOS-related proteins via the TIMM23-TIMM17A translocase, limiting OXPHOS biogenesis under mitochondrial stress conditions.\",\n      \"method\": \"DNAJC15 degradation assay, OMA1 cleavage assay, AFG3L2 functional dependence, protein import assay with TIMM23/TIMM17A, OXPHOS biogenesis measurement\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays establishing substrate relationship, preprint not yet peer-reviewed\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"AFG3L2 is a mitochondrial inner-membrane AAA+ metalloprotease that forms homo-oligomeric complexes and hetero-oligomeric complexes with paraplegin (SPG7) to perform ATP-dependent protein quality control; its established substrates include MrpL32 (for mitoribosome maturation), SLC25A39 (regulated by iron-sulfur cluster sensing), MMADHC (regulating cobalamin flux), and VISA/MAVS (modulating antiviral signaling), and it processes OPA1 in an OMA1-dependent manner to regulate mitochondrial fusion—with disease mutations in the proteolytic domain causing proteotoxic stress that hyperactivates OMA1 and impairs fusion, while ATPase-domain mutations directly disrupt OPA1 processing, and overall loss of AFG3L2 impairs mitochondrial ribosome assembly, respiration, Ca²⁺ buffering, and axonal development.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"AFG3L2 is a mitochondrial inner-membrane AAA+ metalloprotease that serves as a central hub for mitochondrial protein quality control, ribosome biogenesis, cristae maintenance, and metabolite homeostasis. It forms homo-oligomeric complexes and hetero-oligomeric complexes with paraplegin (SPG7), processing substrates including MrpL32 (mitoribosome maturation), SLC25A39 (glutathione transport regulated by iron-sulfur cluster sensing), MMADHC (cobalamin trafficking), and MAVS (innate immune signaling), with substrate recognition driven by specific degron sequences and a preference for hydrophobic/small polar residues at the P1' cleavage position [PMID:29932645, PMID:38157846, PMID:41411131, PMID:41599057]. Loss of AFG3L2 proteolytic activity triggers mitochondrial proteotoxic stress that hyperactivates the stress protease OMA1, leading to excessive OPA1 cleavage, mitochondrial fragmentation, impaired Ca²⁺ buffering, and activation of the integrated stress response, whereas ATPase-domain mutations directly disrupt OPA1 processing through a mechanistically distinct pathway [PMID:30910913, PMID:32219868, PMID:41883704]. Heterozygous mutations in AFG3L2 cause spinocerebellar ataxia type 28 (SCA28) and dominant optic atrophy, with Purkinje cell degeneration driven by respiratory chain dysfunction and glutamate-mediated Ca²⁺ excitotoxicity [PMID:20208537, PMID:25485680, PMID:32219868].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of AFG3L2 as a mitochondrial protein homologous to paraplegin and yeast m-AAA protease subunits established the gene as a candidate mitochondrial protease in mammals.\",\n      \"evidence\": \"Immunofluorescence and EST database screening in human cells\",\n      \"pmids\": [\"10395799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No demonstration of proteolytic activity\", \"No functional characterization beyond localization\", \"Oligomeric state unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstration that AFG3L2 forms both homo-oligomeric and hetero-oligomeric (with paraplegin) m-AAA complexes, and that its loss causes severe axonal developmental defects exceeding those of paraplegin loss, established AFG3L2 as the dominant functional subunit of the mammalian m-AAA protease.\",\n      \"evidence\": \"Afg3l2-null and missense knock-in mice compared with paraplegin-deficient mice; histology and electron microscopy\",\n      \"pmids\": [\"18337413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous substrates unidentified\", \"Mechanism of axonal degeneration unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Haploinsufficiency of Afg3l2 causing Purkinje cell dark degeneration with ROS elevation and respiratory chain dysfunction demonstrated that even partial loss of m-AAA protease activity is sufficient for neurodegeneration, establishing dose sensitivity.\",\n      \"evidence\": \"Afg3l2 heterozygous knockout mice; ROS measurements, electron microscopy, cerebellar assays\",\n      \"pmids\": [\"19625515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate accumulation not profiled\", \"Whether ROS is cause or consequence unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linking heterozygous proteolytic-domain missense mutations to SCA28 and demonstrating respiratory and proteolytic deficiency in yeast reconstitution defined AFG3L2 as a disease gene and pinpointed the M41 peptidase domain as critical for function.\",\n      \"evidence\": \"Yeast complementation assay expressing human AFG3L2 mutants; respiratory growth and complex IV activity in five SCA28 families\",\n      \"pmids\": [\"20208537\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mammalian substrates still unidentified\", \"Mechanism connecting proteolytic deficiency to complex IV loss unclear\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Characterization of a homozygous Y616C mutation revealed that disease severity correlates with oligomerization impairment, showing that complex assembly is a regulated step distinct from catalytic activity.\",\n      \"evidence\": \"Yeast complementation and blue native PAGE in patient fibroblasts\",\n      \"pmids\": [\"22022284\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of oligomerization defect unknown\", \"Effect on substrate spectrum not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Conditional Purkinje-cell knockout established that AFG3L2 is required cell-autonomously for mitoribosome assembly and mitochondrial translation, while AFG3L2-null MEFs revealed that mitochondrial fragmentation impairs ER–mitochondria Ca²⁺ transfer — rescued by OPA1 overexpression — linking protease loss to both translation and organelle dynamics.\",\n      \"evidence\": \"Purkinje-cell-specific Afg3l2 KO mouse with mitoribosome assembly and translation assays; Afg3l2−/− MEFs with Ca²⁺ imaging and OPA1 rescue\",\n      \"pmids\": [\"23041622\", \"22678058\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How AFG3L2 promotes ribosome assembly (direct MrpL32 processing vs. indirect) not yet resolved at this point\", \"OPA1 processing mechanism not delineated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Two advances clarified upstream regulation and downstream consequences: AFG3L2 tyrosine phosphorylation regulates SPG7 processing and complex activation, while in vivo rescue of ataxia by reducing mGluR1 signaling or glutamate levels placed AFG3L2 deficiency upstream of Ca²⁺ excitotoxicity in Purkinje cells.\",\n      \"evidence\": \"SPG7 processing and phosphorylation assays in cells; Afg3l2 haploinsufficient mice with genetic (mGluR1) and pharmacological (ceftriaxone) rescue\",\n      \"pmids\": [\"24767997\", \"25485680\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of kinase phosphorylating AFG3L2 unknown\", \"Whether Ca²⁺ excitotoxicity is the sole degenerative pathway unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"In vitro reconstitution defined AFG3L2's peptidase specificity (hydrophobic/small polar P1' preference) and identified the MrpL32 presequence degron as the recognition element, while SCA28 knock-in MEFs showed that proteolytic-domain mutations cause proteotoxic stress that drives OPA1 loss — reversible by inhibiting mitochondrial translation with chloramphenicol.\",\n      \"evidence\": \"Purified AFG3L2 with MS-based cleavage profiling and MrpL32 degron mutagenesis; M665R knock-in MEFs with Seahorse, OPA1 blot, and chloramphenicol rescue\",\n      \"pmids\": [\"29932645\", \"30389403\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full substrate repertoire uncharacterized\", \"Structural basis of degron recognition unknown at atomic level\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The cryo-EM structure of substrate-engaged AFG3L2 revealed specialized pore-loop arrangements for ATP-dependent substrate translocation, and functional mapping showed that disease mutations cluster at these unique structural features — providing a structural framework for genotype-phenotype correlations. Separately, proteolytic-domain SCA28 mutations were shown to trigger OMA1 hyperactivation as the proximate cause of OPA1 clipping and fusion failure.\",\n      \"evidence\": \"Cryo-EM of substrate-bound AFG3L2 catalytic core with disease-variant mutagenesis; SCA28 patient fibroblasts, CRISPR KO cells, and MEFs with OMA1 analysis and chloramphenicol rescue\",\n      \"pmids\": [\"31327635\", \"30910913\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length complex structure with membrane domain not resolved\", \"How proteotoxic stress activates OMA1 at a molecular level remains unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"ATPase-domain mutations were shown to cause dominant optic atrophy through a mechanism distinct from SCA28: direct disruption of OPA1 processing rather than proteotoxicity-mediated OMA1 hyperactivation, establishing that different AFG3L2 domains produce distinct diseases through mechanistically separable pathways.\",\n      \"evidence\": \"Patient fibroblasts with ATPase-domain mutations; OPA1 processing and mitochondrial morphology compared to proteolytic-domain mutants; yeast complementation\",\n      \"pmids\": [\"32219868\", \"32600459\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AFG3L2 directly processes OPA1 or acts indirectly still debated\", \"Tissue-specific vulnerability (retinal ganglion cells vs. Purkinje cells) unexplained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identification of SLC25A39 as an AFG3L2 substrate whose degradation is gated by mitochondrial iron-sulfur cluster–dependent cysteine modification established AFG3L2 as a sensor-coupled quality control protease that integrates metabolite status with substrate turnover.\",\n      \"evidence\": \"Co-IP mass spectrometry, CRISPR KO, matrix loop 1 and cysteine mutagenesis, SLC25A39 stability assays in mammalian cells\",\n      \"pmids\": [\"38157846\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other AFG3L2 substrates are similarly metabolite-gated is unknown\", \"Structural basis of Fe-S cluster sensing not resolved\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Expansion of the AFG3L2 substrate repertoire to include MMADHC (linking protease loss to cobalamin/succinyl-CoA dysregulation and hematopoietic stem cell failure) and MAVS (constitutive degradation controlling antiviral innate immunity) broadened AFG3L2's functional scope beyond neuronal and respiratory contexts to metabolism and immune signaling.\",\n      \"evidence\": \"Afg3l2 KO mouse with metabolomics and MMADHC knockdown rescue of HSC defects; AFG3L2 knockdown with MAVS degradation assay and in vivo antiviral model\",\n      \"pmids\": [\"41411131\", \"41599057\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Comprehensive substrate profiling (degradomics) not yet performed\", \"Physiological relevance of MAVS regulation by AFG3L2 in human immune cells untested\", \"MMADHC degradation mechanism (degron, cofactor dependence) uncharacterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the complete substrate repertoire of AFG3L2, the molecular mechanism by which proteotoxic stress activates OMA1, whether AFG3L2 directly cleaves OPA1, and the structural and regulatory basis for tissue-specific vulnerability (Purkinje cells vs. retinal ganglion cells vs. HSCs) in different AFG3L2-linked diseases.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No comprehensive degradomics performed\", \"OMA1 activation mechanism at molecular level unknown\", \"Full-length membrane-embedded AFG3L2 complex structure unavailable\", \"Tissue-specific cofactors or regulators not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3, 10, 13, 14, 17, 19]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [13, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [3, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [0, 1, 5, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [5, 10, 14, 17, 19]},\n      {\"term_id\": \"R-HSA-1852241\", \"supporting_discovery_ids\": [5, 6, 9]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [17, 19]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 15, 20]}\n    ],\n    \"complexes\": [\n      \"m-AAA protease homo-oligomeric complex\",\n      \"m-AAA protease hetero-oligomeric complex (AFG3L2/SPG7)\"\n    ],\n    \"partners\": [\n      \"SPG7\",\n      \"OMA1\",\n      \"OPA1\",\n      \"MRPL32\",\n      \"SLC25A39\",\n      \"MMADHC\",\n      \"MAVS\",\n      \"DNAJC15\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}